A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690,550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690,550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD
To evaluate the dose-response relationship of 5 dose of CP-690,550, compared to placebo for the treatment of signs and symptoms in patients with active RA who failed an adequate trial of therapy with at least 1 DMARD in a 12-week therapy.
Inclusion Criteria:
Exclusion Criteria:
Yotukaidou, Chiba, Japan
Iiduka, Fukuoka, Japan
Sawara-ku, Fukuoka, Japan
Koushi, Kumamoto, Japan
Ohmura, Nagasaki, Japan
Ureshino-shi, Saga-ken, Japan
Kawagoe-shi, Saitama, Japan
Arakawa-ku, Tokyo, Japan
Bunkyo-ku, Tokyo, Japan
Musashimurayama-shi, Tokyo, Japan
Setagaya-ku, Tokyo, Japan
Shinjyuku-ku, Tokyo, Japan